UPDATE: BMO Capital Markets Raises PT on Regulus Therapeutics Following 2Q13 Operating Results

In a report published Wednesday, BMO Capital Markets analyst Jim Birchenough reiterated an Outperform rating on Regulus Therapeutics (NASDAQ: RGLS ), and raised the price target from $10.00 to $15.00. In the report, BMO Capital Markets noted, “RGLS reported 2Q13 operating results late yesterday and provided an update on key